RE: Combo trials19 Aug 2018 19:21
that is exactly what the addition of amplivant is doing, you see its not just about stressing the cancer its also about Interferon Gamma .. so you have autophagy in the cancer but you need inflammation to upregulate the citrullinated epitopes on stressed cells, so your now active CD4's are giving the cancer plenty of the cytokine starting that chain reaction. IMHO we have to run moditope into trial and see exactly what is going on. Lets get patient data, because stressing a cancer is potentially creating a dangerous game of cat and mouse if you are forcing the issue but who knows what off the shelf product exists that could initiate this process ( that would give you a clear heads up with data)
so Amplivant creates a CD4 t cell that is more stressful to cancer .... its called the TH1 differential
Th1 cells primarily produce interferon (IFN)-g and interleukin (IL)-2,
this is how it gets interesting so our TH1 cd4 act against any other T cell that is trying to regulate the response calm it down as this is not what we want ... because we are trying to stress the cancer harder
There is perhaps no more dramatic demonstration of the functional consequence of the diametrically opposing roles of Th1 and Th2 cells than the ability of inbred mouse strains to respond to infection with Leishmania major, an intracellular parasite. Most inbred mouse strains (such as B10.D2) respond to L. major infection with a Th1-like response, clearing the infection.
In contrast,
BALB/c strains, which respond with a Th2 response, are unable to do so, and ultimately succumb to infection.5
Sign In
Follow the stocks
